Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOPHO-DBH AML 2012 (Pediatric AML 0–18 years)
2024-518254-16-00Phase 3Authorised
- Sponsor
- Region Västra Götaland
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, single-arm trial of etoposide, cytarabine, daunorubicin, mitoxantrone and fludarabine in acute myeloid leukemia (AML), sponsored by Region Västra Götaland. Primary endpoints: Proportion of patients with MRD <0.1% after first induction, Proportion of patients with MRD <0.1% after second induction and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
etoposidecytarabinedaunorubicinmitoxantronefludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-518254-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518254-16-00.